[1] Sahin U, Türeci Ö, Personalized vaccines for cancer immunotherapy[J]. Science, 2018, 359(6382): 1355-1360.
[2] Liu C, Liu X, Xiang XC, et al. A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy[J]. Nat Nanotechnol, 2022, 17(5): 531-540.
[3] Shi CR, Zhang QY, Yao YY, et al. Targeting the activity of T cells by membrane surface redox regulation for cancer theranostics[J]. Nat Nanotechnol, 2023, 18(1): 86-97.
[4] Shen W, Liu T, Pei P, et al. Metabolic Homeostasis-Regulated Nanoparticles for Antibody-Independent Cancer Radio-Immunotherapy[J]. Adv Mater, 2022, 34(51): e2207343.
[5] Pei P, Shen W, Zhang Y, et al. Radioactive nano-oxygen generator enhance anti-tumor radio-immunotherapy by regulating tumor microenvironment and reducing proliferation[J]. Biomaterials, 2022, 280: 121326.
[6] Ni J, Zhou H, Gu J, et al. Bacteria-assisted delivery and oxygen production of nano-enzyme for potent radioimmunotherapy of cancer[J]. Nano Res, 2022, 15(8): 7355-7365.
[7] Qi Z, Pei P, Zhang Y, et al. 131I-αPD-L1 immobilized by bacterial cellulose for enhanced radio-immunotherapy of cancer[J]. J Control Release, 2022, 346: 240-249.
[8] Matsumura Y and Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs[J]. Cancer Res, 1986, 46(12 Pt 1): 6387-6392.
[9] Sindhwani S, Syed AM, Ngai J, et al. The entry of nanoparticles into solid tumours[J]. Nat Mater, 2020, 19(5): 566-575.
[10] Zhu M, Zhuang J, Li Z, et al. Machine-learning-assisted single-vessel analysis of nanoparticle permeability in tumour vasculatures[J]. Nat Nanotechnol, 2023, 18(6): 657-666.
[11] Wei Y, Wu J, Wu Y, et al. Prediction and Design of Nanozymes using Explainable Machine Learning[J]. Adv Mater, 2022, 34(27): e2201736.
[12] Zhuang J, Midgley A, Wei Y, et al. Machine Learning-assisted Nanozyme Design: Lessons from Materials and Engineered Enzymes[J]. Adv Mater, 2023.
[13] Saxena M, van der Burg SH, Melief CJM, et al. Therapeutic cancer vaccines[J]. Nat Rev Cancer, 2021, 21(6): 360-378.
[14] Shemesh CS, Hsu JC, Hosseini I, et al. Personalized cancer vaccines: Clinical landscape, challenges, and opportunities[J]. Mol Ther, 2021, 29(2): 555-570.
[15] Lv M, Chen M, Zhang R, et al. Manganese is critical for antitumor immune responses via cgas-sting and improves the efficacy of clinical immunotherapy[J]. Cell Res, 2020, 30(11): 966-979.
[16] Li T, Song R, Sun F, et al. Bioinspired magnetic nanocomplexes amplifying sting activation of tumor-associated macrophages to potentiate cancer immunotherapy[J]. Nano Today, 2022, 43.
[17] Chen F, Li T, Zhang H, et al. Acid-ionizable iron nanoadjuvant augments sting activation for personalized vaccination immunotherapy of cancer[J]. Adv Mater, 2022, 35(10): e2209910.
[18] Shang Q, Dong Y, Su Y, et al. Local scaffold-assisted delivery of immunotherapeutic agents for improved cancer immunotherapy[J]. Adv Drug Deliv Rev, 2022, 185: 114308.
[19] Wang F, Su H, Lin R, et al. Supramolecular tubustecan hydrogel as chemotherapeutic carrier to improve tumor penetration and local treatment efficacy[J]. ACS Nano, 2020, 14(8): 10083-10094.
[20] Wang F, Su H, Xu D, et al. Therapeutic supramolecular tubustecan hydrogel combined with checkpoint inhibitor elicits immunity to combat cancer[J]. Biomaterials, 2021, 279: 121182.
[21] Wang F, Su H, Xu D, et al. Tumour sensitization via the extended intratumoural release of a STING agonist and camptothecin from a self-assembled hydrogel[J]. Nat Biomed Eng, 2020, 4(11): 1090-1101.
[22] Wang F, Xu D, Su H, et al. Supramolecular prodrug hydrogelator as an immune booster for checkpoint blocker-based immunotherapy[J]. Sci Adv, 2020, 6(18): eaaz8985.
[23] Wang F, Huang Q, Su H, et al. Self-assembling paclitaxel-mediated stimulation of tumor-associated macrophages for postoperative treatment of glioblastoma[J]. Proc Natl Acad Sci USA, 2023, 120(18): e2204621120.
[24] Zhang J, Chen C, Li A, et al. Immunostimulant hydrogel for the inhibition of malignant glioma relapse post-resection[J]. Nat Nanotechnol, 2021, 16(5): 538-548.
[25] Guo X, Jiang H, Shi B, et al. Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma[J]. Front Pharmacol, 2018, 9: 1118.
[26] Choi B D, Yu X, Castano A P, et al. CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma[J]. J Immunother Cancer. 2019, 7(1): 304.
[27] Lu Y, Xue J, Deng T, et al. Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer[J]. Nat Med, 2020, 26(5): 732-740.
[28] Eyquem J, Mansilla-Soto J, Giavridis T, et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection[J]. Nature, 2017, 543(7643): 113-117.
[29] Stadtmauer E A, Fraietta J A, Davis M M, et al. CRISPR-engineered T cells in patients with refractory cancer[J]. Science, 2020, 367(6481): eaba7365.
[30] Rosenblum D, Gutkin A, Kedmi R, et al. CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy[J]. Sci Adv, 2020, 6(47): eabc9450.
[31] Nie J-J, Liu Y, Qi Y, et al. Charge-reversal nanocomolexes-based CRISPR/Cas9 delivery system for loss-of-function oncogene editing in hepatocellular carcinoma[J]. J Control Release, 2021, 333: 362-373.
[32] Cao F, Jin L, Gao Y, et al. Artificial-enzymes-armed Bifidobacterium longum probiotics for alleviating intestinal inflammation and microbiota dysbiosis[J]. Nat Nanotechnol, 2023, 18(6): 617-627.
[33] Yue Y, Xu J, Li Y, et al. Antigen-bearing outer membrane vesicles as tumour vaccines produced in situ by ingested genetically engineered bacteria[J]. Nat Biomed Eng, 2022, 6(7): 898-909.
[34] Yang Z, Zhu Y, Dong Z, et al. Engineering bioluminescent bacteria to boost photodynamic therapy and systemic anti-tumor immunity for synergistic cancer treatment[J]. Biomaterials, 2022, 281: 121332.
[35] Pan P, Dong X, Chen Y, et al. Engineered bacteria for enhanced radiotherapy against breast carcinoma[J]. ACS Nano, 2022, 16(1): 801-812.
[36] Vargason AM, AnselmoAC, Mitragotri S. The Evolution of Commercial Drug Delivery Technologies[J]. Nat Biomed Eng. 2021, 5(9): 951-967.
[37] 国家药品监督管理局. 2022年01月11日药品批准证明文件待领取信息发布,2023年01月03日药品批准证明文件送达信息发布. [EB/OL]. [2022-01-11, 2023-01-03]. https://www.nmpa.gov.cn/.
[38] 国家药品监督管理局药品审评中心. 信息公开, 受理品种信息. [EB/OL]. https://www.cde.org.cn/.
[39] 药物临床试验登记与信息公示平台. [EB/OL]. http://www.chinadrugtrials.org.cn/.